161 completed. 161 Phase 1, 21 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 161 | Completed 161 |
| Phase 2 | 21 | Completed 21 |
Follow Psoriasis: new trials by email Literature Review of Psoriasis trials Research Report on Psoriasis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Maximal Usage Pharmacokinetics and Safety Study of ARQ-154 Foam 0.3% in Pediatric Participants With Scalp and Body Psoriasis ARQ-154 Foam 0.3% - Psoriasis | Phase 1 | Completed | Arcutis Biotherapeutics, Inc. | 22 | 2025-12-15 | 2026-05-22 |
| Pharmacokinetic, Safety and Immunogenicity Study of New Process CMAB015 and Cosentyx in Healthy Volunteers Secukinumab 150mg s.c. - Psoriasis | Phase 1 | Completed | Taizhou Mabtech Pharmaceutical Co.,Ltd | 114 | 2025-12-15 | 2026-10-21 |
| A Drug-Drug Interaction Study Between HS-10374 Tablets and Drospirenone and Ethinyl Estradiol Tablets(Yasmin®) HS-10374 tablets, Drospirenone and Ethinyl Estradiol tablets - Psoriasis (PsO) | Phase 1 | Completed | Hansoh BioMedical R&D Company | 18 | 2025-05-28 | 2025-09-18 |
| Evaluate the Safety and Pharmacokinetics/Pharmacodynamics of HS-20118 HS-20118, HS-20118 placebo - Psoriasis | Phase 1 | Completed | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 60 | 2025-05-02 | 2026-11-04 |
| Combined Use of Cyclosporine and Metformin in Treatment of Psoriasis vs Cyclosporine Alone Cyclosporin (CSA), Metformin (500 mg Twice a day) - Psoriasis | Phase 1 | Completed | Cairo University | 32 | 2024-12-19 | 2026-01-29 |
| Pharmacokinetic Interactions Between Hemay005 Tablets and Midazolam Maleate Tablets Hemay005, Midazolam maleate - Psoriasis | Phase 1 | Completed | Ganzhou Hemay Pharmaceutical Co., Ltd | 20 | 2024-12-12 | 2025-12-03 |
| Bioequivalence Test of Hemay005 Tablets Hemay005 - Psoriasis | Phase 1 | Completed | Ganzhou Hemay Pharmaceutical Co., Ltd | 28 | 2024-09-15 | 2025-03-18 |
| To Evaluate the Pharmacokinetics of Hemay005 Tablets in Patients With Renal Impairment Hemay005 - Psoriasis | Phase 1 | Completed | Ganzhou Hemay Pharmaceutical Co., Ltd | 26 | 2024-05-07 | 2025-12-04 |
| Phase I Randomized, Open-label, Parallel-controlled, Pharmacokinetic and Safety Study of BR201 Injection Versus Cosentyx in Healthy Male Subjects BR201, Cosentyx（Secukinumab ） - Psoriasis | Phase 1 | Completed | BioRay Pharmaceutical Co., Ltd. | 88 | 2024-02-21 | 2025-06-24 |
| A Clinical Trial of TQH3906 Capsules in Healthy Volunteers TQH3906 capsule, TQH3906 placebo - Psoriasis | Phase 1 | Completed | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | 96 | 2024-02-02 | 2025-07-16 |
| A Study to Evaluate the Safety and Tolerability, and the Efficacy of Si-544 in Adults With Psoriasis Vulgaris or Psoriatic Arthritis si-544, Placebo - Psoriasis Vulgaris, Psoriatic Arthritis | Phase 1 | Completed | selectION Therapeutics GmbH | 45 | 2024-01-22 | 2025-07-03 |
| Proof of Concept Study of AX-158 in Patients With Mild to Moderate Plaque Psoriasis AX-158, Placebo - Psoriasis, Plaque Psoriasis | Phase 1 / Phase 2 | Completed | Artax Biopharma Inc | 31 | 2023-11-30 | 2025-10-03 |
| A Clinical Study of TQH2929 in Healthy Adult Subjects TQH2929 injection, Placebo injection - Psoriasis | Phase 1 | Completed | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | 40 | 2023-11-21 | 2025-03-25 |
| A Study to Test How Well Different Doses of BI 765250 Are Tolerated by People With a Skin Disease Called Plaque Psoriasis BI 765250, Placebo - Psoriasis | Phase 1 | Completed | Boehringer Ingelheim | 64 | 2023-04-27 | 2025-03-07 |
| A Safety, Tolerability and Pharmacokinetics Study of Topical Ointment YR001 in Adult Healthy Volunteers YR001 Dose A on low body surface area, YR001 Dose A on middle body surface area, YR001 Dose A on high body surface area - Atopic Dermatitis, Psoriasis | Phase 1 | Completed | Hangzhou Yirui Pharmaceutical Technology Co., Ltd | 54 | 2023-04-08 | 2024-01-24 |
| Pharmacokinetic, Safety and Immunogenicity Study of CMAB015 and Cosentyx in Healthy Volunteers Secukinumab - Psoriasis | Phase 1 | Completed | Taizhou Mabtech Pharmaceutical Co.,Ltd | 130 | 2023-02-15 | 2024-04-10 |
| HB0034 in Patients With Generalized Pustular Psoriasis (GPP) HB0034 - Generalized Pustular Psoriasis | Phase 1 | Completed | Shanghai Huaota Biopharmaceutical Co., Ltd. | 9 | 2022-11-06 | 2024-01-23 |
| Ethoximod Pharmacokinetics In Healthy Subjects Ethoximod - Psoriasis | Phase 1 | Completed | Longevity Inc. | 65 | 2022-09-01 | 2024-04-11 |
| A Study on Pharmacokinetics and Safety of BAT2506 Injection Versus Simponi® BAT2506 injection, Simponi® (EU commercially available product), Simponi® (US commercially available product) - Psoriatic Arthritis | Phase 1 | Completed | Bio-Thera Solutions | 375 | 2022-08-01 | 2023-08-28 |
| A Clinical Study With Adalimumab Biosimilar Humira® (adalimumab) AC Pen [Reference Product], Adalimumab Richmond [Test Product] - Pharmacokinetics, Safety Issues | Phase 1 | Completed | Laboratorios Richmond S.A.C.I.F. | 150 | 2022-08-01 | 2024-03-04 |
Showing 20 of 161. Sign in to see all of them.
Arthritis, Psoriatic (18) · Arthritis, Rheumatoid (9) · Crohn Disease (5) · Dermatitis, Atopic (5) · Spondylitis, Ankylosing (5) · Autoimmune Diseases (4) · Arthritis (3) · Arthritis, Juvenile (3) · Axial Spondyloarthritis (3) · Hidradenitis Suppurativa (3) · Plaque, Amyloid (3) · Colitis, Ulcerative (2) · Dermatitis (2) · Drug-Related Side Effects and Adverse Reactions (2)
Skin Diseases, Papulosquamous (161) · Skin and Connective Tissue Diseases (161) · Skin Diseases (159) · Joint Diseases (22) · Musculoskeletal Diseases (22) · Immune System Diseases (21) · Arthritis (19) · Bone Diseases (18) · Spinal Diseases (18) · Spondylarthritis (18) · Spondylarthropathies (18) · Spondylitis (18) · Connective Tissue Diseases (12) · Autoimmune Diseases (10)
calcipotriene (11) · Midazolam (6) · Ustekinumab (6) · deucravacitinib (6) · secukinumab (6) · Hemay005 (5) · Betamethasone (4) · Cyclosporine (4) · Caffeine (3) · Methotrexate (3) · Omeprazole (3) · Warfarin (3) · brodalumab (3) · guselkumab (3) · Adalimumab (2)
Bristol-Myers Squibb (7) · Eli Lilly and Company (7) · GlaxoSmithKline (6) · Pfizer (6) · Bausch Health Americas, Inc. (4) · Bio-Thera Solutions (4) · Boehringer Ingelheim (4) · Novartis Pharmaceuticals (4) · AbbVie (3) · Bayer (3) · Evelo Biosciences, Inc. (3) · Ganzhou Hemay Pharmaceutical Co., Ltd (3) · Affibody (2) · Almirall, S.A. (2) · Arcutis Biotherapeutics, Inc. (2)
United States (61) · China (24) · Germany (24) · United Kingdom (13) · Australia (12) · Canada (10) · New Zealand (9) · France (4) · Japan (4) · Moldova (4) · Netherlands (4) · Austria (3) · Bulgaria (3) · Switzerland (3) · Poland (2)
Duncan McHale, MD, PhD (2) · James Krueger, MD, PHD (2) · Richard Gregg, MD (2)
PMID 19587341, PMID 20231202, PMID 20811392, PMID 22622425, PMID 22653877, PMID 23607128, PMID 27859546, PMID 28814432, PMID 29030361, PMID 29150844, PMID 29275332, PMID 30100374, PMID 30574672, PMID 30937241, PMID 31054118, PMID 32407591, PMID 32767679, PMID 32845114, PMID 33241960, PMID 34988162, PMID 35262901, PMID 36417156, PMID 36422852, PMID 36566344, PMID 36919398, PMID 37184136, PMID 37212315, PMID 37215725, PMID 37300792, PMID 37356077, PMID 37483071, PMID 38231873, PMID 39104539, PMID 39224901, PMID 39455575, PMID 40520205, PMID 41452420, PMID 41545329, PMID 42012633
2017 (5), 2016 (4), 2014 (2), 2015 (2), 2018 (2), 2019 (2), 2009 (1), 2023 (1)